We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Oxygen Deprivation Activates Tumor Survival Genes in Solid Tumors

By LabMedica International staff writers
Posted on 15 Mar 2015
Print article
Image: Photomicrograph of mouse embryonic cells that have been programmed to overexpress Higd1a protein (shown in green). This protein slows down the metabolism of cancer cells, allowing them to hibernate and survive long-term (Photo courtesy of the University of California, San Francisco).
Image: Photomicrograph of mouse embryonic cells that have been programmed to overexpress Higd1a protein (shown in green). This protein slows down the metabolism of cancer cells, allowing them to hibernate and survive long-term (Photo courtesy of the University of California, San Francisco).
A possible new approach for treating reoccurring tumors would target the protein hypoxia-inducible gene domain family member 1A (Higd1a).

Higd1a is a survival factor induced by hypoxia-inducible factor 1 (HIF-1). HIF-1 regulates many responses to oxygen deprivation but is frequently absent in viable cells within the hypoxic perinecrotic regions of solid tumors. Cells in this region are deprived of both oxygen and nutrients, which promote their resistance to therapy.

Since Higd1a decreases tumor growth but promotes tumor cell survival in vivo, investigators at the University of California, San Francisco (USA) have examined how the HIGD1A gene becomes activated in the absence of its usual inducer, HIF-1.

They reported in the February 12, 2015, online edition of the journal Cell Reports that the human HIGD1A gene was located on chromosome 3p22.1, where many tumor suppressor genes reside. Consistent with this, the HIGD1A gene promoter was differentially methylated in human cancers, preventing its hypoxic induction. However, when hypoxic tumor cells were confronted with glucose deprivation, DNA methyltransferase activity was inhibited, enabling HIGD1A expression, metabolic adaptation, and possible dormancy induction. Under these conditions Higd1a protein was available to interact with the mitochondrial electron transport chain to repress oxygen consumption, enhance AMPK (AMP-dependent kinase) activity, and lower cellular ROS (reactive oxygen species) levels.

Studies conducted in vivo with tumor cells that had been genetically engineered to overexpress HIGD1A, demonstrated dramatically repressed tumor growth but significantly enhanced overall tumor survival, and these effects were even seen in mice that lacked the HIF-1 protein.

Based on these results, the authors suggested that, "Our findings therefore reveal important new roles for this family of mitochondrial proteins in cancer biology."

Related Links:

University of California, San Francisco


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.